NORTECH SYSTEMS INC (NSYS) stock intrinsic value fair value estimate & owner earnings analysis

Nortech Systems is a contract manufacturer based in Maple Grove, Minnesota. It designs and builds electromedical devices, medical imaging assemblies, industrial electronics and aerospace and defense products to its customers' specifications, from plants in Minnesota, Monterrey (Mexico) and Suzhou (China). The China plant is small, with about $1.0 million of long-term assets. In 2025 sales were $118.4 million: medical imaging $40.0 million, medical devices $31.9 million, industrial $30.9 million and aerospace and defense $15.5 million. One customer was 32.2% of 2025 sales (27.7% in 2024). A majority shareholder group can control company decisions. What the numbers show. Across the ten years 2016 to 2025, sales stayed between $104 million (2020) and $139 million (2023), yet the cash left for shareholders was close to nothing. We removed one-time items (the 2021 Paycheck Protection Program loan forgiveness of $6.2 million, the $5.2 million Employee Retention Credit recorded in 2021 and collected in 2022 and 2023, and a $2.4 million deferred tax benefit in 2023), subtracted stock compensation (about $0.5 million a year recently) as a real cost, and counted equipment bought under finance leases as capital spending ($637,000 in 2025). On that basis the ten-year total of cash left to shareholders after interest is about negative $1.6 million, against $6.3 million of interest paid. We also set aside swings in receivables, inventory, contract assets and payables, because they reverse over time; they still matter, because the borrowings below have funded them. Operating profit was $975,000 in 2025 (0.8% of sales) after a $195,000 loss in 2024. Where the business stands. The one structural change visible in the filings is the 2024 to 2025 restructuring: the Blue Earth, Minnesota plant closed in December 2024 and was sold in July 2025, and staffing was cut in February 2025. In the first half of 2026 sales were $63.9 million (up 10.9%), gross margin was 16.3% (13.7% in the first half of 2025) and operating profit was $670,000 against a loss of $871,000. The last four quarters together earned about $2.5 million of operating profit. Two cautions: second-quarter 2026 operating profit ($623,000) was below the second quarter of 2025 ($742,000) even though sales rose, and operating cash flow was negative in the first half of both 2025 and 2026 (negative $2.4 million in 2026) because growth ties up receivables, inventory and contract assets. The $77.3 million order backlog at the end of 2025 (up 17.4%) includes $15.2 million already booked as sales, so about $62 million is still to be recognized. Debt. Borrowings at June 30, 2026 were $7.9 million on the revolving credit line, a $2.1 million term loan and $0.8 million of finance leases: $10.7 million in all, about $3.58 per share on 2.999 million diluted shares. We treat the $1.4 million of cash as needed to run the business and carry the debt at face value. In March 2026 a new Associated Bank facility (a revolver of up to $15.0 million and a $2.2 million term loan, both maturing March 2029, priced at 2.00% and 2.25% over the benchmark rate) replaced the Bank of America line, which, the company says, needed multiple amendments and default waivers after earnings fell short of its covenants following the 2024 and 2025 restructuring. The new facility requires a fixed charge coverage ratio of at least 1.10 and is secured by substantially all U.S. assets. How we value it. We value the cash the business produces before paying its lenders (operating cash after taxes, stock compensation and necessary capital spending, with interest added back), then subtract the $10.7 million owed. Per share, that cash flow was $0.75 in 2022, $2.03 in 2023, negative $0.13 in 2024 and $0.04 in 2025. For the middle case we use the median of those four years, $0.39 per share or about $1.18 million a year. We use the four most recent full years because they reflect today's customer pricing (the company points to post-pandemic repricing) and leave out the pandemic and component-shortage years of 2020 and 2021, which the bear case models separately; the window still holds a boom (2022 and 2023), a restructuring trough (2024) and a recovery (2025). The last four quarters of operating profit ($2.5 million) point to a similar or somewhat higher level. The full ten-year median is only $0.07 per share, about $0.2 million a year, and is what the bear case leans on. Because the borrowings are about nine times the cash flow we count on, each $100,000 a year of cash flow moves the share value by about $0.56. Growth check. Cash flow before interest was $0.04 per share in 2025 against negative $0.13 in 2024. The middle case starts year one at $0.39, above that trailing figure. The reasons are dated in the filings: the Blue Earth closure (December 2024, sold July 2025), the February 2025 staffing reduction, and gross margin of 16.3% in the first half of 2026 against 13.7% a year earlier, with operating profit of $670,000 against a loss. After year one we assume no growth. Middle case: $2.99 per share. The business holds about $1.18 million a year of cash flow indefinitely; sales have been between $104 million and $139 million in every one of the last ten years, in work done at facilities certified to ISO 13485 (medical) or AS9100 (aerospace) standards. The business is worth about $19.7 million and owes $10.7 million, leaving about $9.0 million, or $2.99 per share. We credit no growth: expansion has consumed cash rather than produced it, and no contract or repeated pattern puts new volume or margin expansion in hand. The backlog is supportive, but we do not count it as growth. Bear case: negative $3.11 per share. Year one looks like 2025 ($0.1 million). The company then repeats the squeeze it lived through in 2020 and 2021, when sales fell 10.5% in 2020 and global supply-chain shortages drove an inventory build in 2021: at today's share count, cash flow of negative $1.2 million, then negative $3.2 million. After that, cash flow settles at $0.37 million a year (the median of the eight years other than 2020 and 2021), which reflects the 32% customer and the post-pandemic customer pricing pressure the company itself describes. The business is worth about $1.4 million and owes $10.7 million, so on this path the company owes more than it is worth, by roughly $9.3 million or $3.11 per share. Cash flow would be below the interest bill for two years and the 1.10 coverage requirement would very likely be breached, as covenants were under the previous lender. Shareholders would be heavily diluted or wiped out; since they are not liable for more than their investment, the practical outcome is shares worth little or nothing. Bull case: $8.93 per share. The company sustains the cash flow it already produced in 2022 ($0.75 per share, about $2.25 million a year), supported by the unrecognized backlog of about $62 million and the lower cost base after the Blue Earth closure. The business is worth about $37.5 million and owes $10.7 million, leaving about $26.8 million. We do not add new products, share gains or a recovering electronics market. What we left out. We credited no growth in any case. Amortization of intangibles is tiny ($18,000 in 2025), so there is no meaningful decay of acquired intangibles to allow for. Challenge to our own view. The strongest argument against the middle case is the cash record: sales were $117 million in 2016 and $118 million in 2025 and the cumulative cash left for shareholders was negative. If the ten-year pattern, not the last four years, is the real earning power, the shares are worth less than nothing after the debt (about negative $2.46 per share). The recent quarters are only a partial answer: second-quarter 2026 operating profit did not exceed a year earlier. Our earlier estimate of September 1, 2026 ($1.50, $3.25 and $10.15) was made on a different basis and is not comparable; no new quarterly results have been filed since then. Why the margin-of-safety price is $1.50. We are not very sure of the earnings level: the four recent years give $1.18 million a year, but the ten-year middle is a sixth of that, and that gap alone is worth about $5.45 per share. The worst plausible outcome is another squeeze like 2020 and 2021 with the lender enforcing the 1.10 coverage requirement; the company has a 32% customer, little cash and no dividend, and lenders are paid first, so the shares could be worth nothing. If we are wrong about the level of cash flow, a result 25% lower than the middle case still leaves the shares worth about $1.35, but a slide to the ten-year level leaves them worth nothing; the same holds if the largest customer cuts back or the new margins do not hold. The price assumes a three-to-five-year holding period: the company says it reinvests profits and does not plan to pay dividends, so the only payoff over that period is slow debt paydown. From $1.50, a 20% annual return over four years implies a share value of about $3.11. That is roughly what we think they are worth today if the improved 2022 to 2025 level merely holds, with no growth and no further margin gains, and it leaves some room for a weaker outcome. A higher price would require the recovery to keep climbing, and we cannot name the evidence for that.